Compare Abeona Therapeutics Inc (ABEO) vs Snap On Incorporated (SNA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Snap On Incorporated — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Snap On Incorporated trades at $400.69 (market cap $21.17B). The key difference: Snap On Incorporated is far larger — about 56.7× Abeona Therapeutics Inc's market cap, and Snap On Incorporated pays a 2.39% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | SNA | |
|---|---|---|
Market Cap | $373.32M | $21.17B |
Sector | Health | Technology |
52-Week High | $7.23 | $413.62 |
52-Week Low | $4.17 | $313.01 |
Enterprise Value | $228.22M | $20.69B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Snap-on Incorporated (SNA) trades at $413.62, up 0.37% with a bullish technical outlook supported by moving averages. The company maintains strong profitability with a 19.6% net income margin and recently beat Q4 2025 earnings. Recent acquisitions like Diesel Laptops for $100 million demonstrate strategic growth initiatives. Analyst consensus is positive with 65% buy ratings and a $407.50 price target.
SNA presents a stable investment with consistent dividend payments and share repurchases, though Q1 2026 earnings miss and elevated valuation ratios pose near-term risks. The stock's technical overbought condition suggests potential consolidation before further upside. Long-term growth depends on successful integration of acquisitions and maintaining premium margins in the competitive tools market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →
